Heparin Sodium
NDC Package 67457-952-04

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Heparin Sodium is a medication used to prevent and treat blood clots. Marketed by Mylan Institutional Llc, this product is identified by NDC 67457-952 and is authorized under FDA application ANDA203851.

Identification & Billing

NDC Package Code
67457-952-04
Package Description
25 VIAL, MULTI-DOSE in 1 CARTON / 4 mL in 1 VIAL, MULTI-DOSE (67457-952-00)
Product Code
67457-952
11-Digit Billing Format
67457095204

Clinical Specifications

Proprietary Name
Heparin Sodium
Dosage Form
-
Usage Information
This medication is used to prevent and treat blood clots. It may be used to prevent and treat blood clots in the lungs/legs (including in patients with atrial fibrillation). It may be used to treat certain blood clotting disorders. It may also be used to prevent blood clots after surgery, during dialysis, during blood transfusions, when collecting blood samples, or when a person is unable to move for a long time. Heparin helps to keep blood flowing smoothly by making a certain natural substance in your body (anti-clotting protein) work better. It is known as an anticoagulant.

Regulatory & Marketing

Labeler Name
Mylan Institutional Llc
FDA Application #
ANDA203851
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-21-2019
End Marketing Date
09-30-2021
Listing Expiration
09-30-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67457-952-04 identifies a specific commercial package of 25 vial, multi-dose in 1 carton / 4 ml in 1 vial, multi-dose (67457-952-00) of Heparin Sodium, labeled by Mylan Institutional Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Mylan Institutional Llc on February 21, 2019. The current certification is valid through September 30, 2021.

What are the primary indications for this medication?

This medication is used to prevent and treat blood clots. It may be used to prevent and treat blood clots in the lungs/legs (including in patients with atrial fibrillation). It may be used to treat certain blood clotting disorders. It may also be used to prevent blood clots after surgery, during dialysis, during blood transfusions, when collecting blood samples, or when a person is unable to move for a long time. Heparin helps to keep blood flowing smoothly by making a certain natural substance in your body (anti-clotting protein) work better. It is known as an anticoagulant.

How is this Mylan Institutional Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67457095204. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
67457-952-04
11-Digit CMS (5-4-2)
67457-0952-04

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.